JHL Biotech has entered into a contract manufacturing master service agreement with Affinita Biotech that covers a development and manufacturing partnership for Affinita’s oncology monoclonal antibodies.

The agreement, extending to 2020, is estimated to be worth up to $20 million in value.  JHL will provide cell line development, process development, and manufacturing expertise. The activities will be carried out in JHL’s Zhubei site in Taiwan as well as at its manufacturing facility in Wuhan, China.

Affinita Biotech, based in South San Francisco, CA, is a preclinical stage biotech company focusing on research and development of certain novel cancer therapies. The company was founded in 2015 by a group of industry experts to focus on research and development of targeted, immunity-based oncology therapies.